Experimental senolytic peptide targeting the FOXO4-p53 interaction

FOXO4-DRI

aka FOXO4 D-retro-inverso peptide · FOXO4-p53 interfering peptide

Evidence grade
Grade D: Preclinical only
for senolytic anti-ageing
User score everyone · n = 11
US FDA Not approved checked 2026-11-13
WADA 2026 Likely prohibited (S0) by class rule · checked 2026-11-13
EU EMA/EU marketing authorization not found; country-specific rules not established in this review. · checked 2026-11-13

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

1 man

small sample · n = 1

Outcome no effect 1 of 1

Side effects fatigue 1 of 1 · injection site 1 of 1

Stopped 0 of 1 Used with other compounds 0 of 1

Everyone

11 people

  • Positive: 2 of 11 (18%)
  • Mixed: 1 of 11 (9%)
  • Negative: 2 of 11 (18%)
  • No effect: 2 of 11 (18%)
  • Unclear: 4 of 11 (36%)
Benefits reported of 11
Benefits reported (n = 11)
ItemReports
Other2 of 11 (18%)
Energy1 of 11 (9%)
Fat loss1 of 11 (9%)
Inflammation1 of 11 (9%)
Sleep1 of 11 (9%)
Side effects reported of 11
Side effects reported (n = 11)
ItemReports
Injection site3 of 11 (27%)
Fatigue2 of 11 (18%)
Blood pressure1 of 11 (9%)
Headache1 of 11 (9%)
Other1 of 11 (9%)
Why people stopped of 11
Why people stopped (n = 11)
ItemReports
Cost2 of 11 (18%)
Other1 of 11 (9%)

Stopped 2 of 11 (18%) Used with other compounds 3 of 11 (27%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “nodules were much more pliable, ROM increased, and pain and inflammation were significantly lower”

  • “my blood pressure peaked at 203/103”

  • “14-15/07/26: no peptides to observe 72 hour pulse for FOXO4-DRI. Bit more fatigue than usual. Nothing else to report.”

  • “I took Foxo4-dri over 4 years ago. It was impressive, I felt 15 years younger in alot of respect.”

  • “I didn't notice fatigue that some point out, but the injection site was quite sore for about 18hrs.”

Read summaries and method notes

Read 1. No verified man aged 45–60 (n=0). Two specific firsthand reports: one described more pliable fibrotic nodules, better range of motion and less pain/inflammation (later stacked with SS-31, KLOW and MOTS-c), the other a severe sustained blood-pressure rise to about 203/103 after two injections, needing extra medication. Blood pressure is the most consequential signal in this tiny corpus.

Read 2. No man aged 45–60; the only clearly male user was in his late 30s and reported fatigue and two days of injection pain after 80 mg in a week, with no noticeable benefit. Nine users from 6 threads: mostly unclear (4) or no effect (2), plus 1 positive ("felt 15 years younger"), 1 mixed (5–11 lb weight loss with lethargy and headaches) and 1 negative. Commonest side effects: sore injection sites for 18 hours to several days, fatigue, headache, over very short 5–21-day cycles. Two limited or ended cycles because 100 mg protocols cost about $1,200.

Note 1. Only two verified firsthand reports were sufficiently specific. One positive course became stacked, limiting attribution.

Note 2. No men 45-60 (a 67-year-old did not state sex). r/BodyHackGuide and promotional guides were excluded. A third-party report about a 46-year-old long-COVID subject was not counted.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

D-retro-inverso peptide that disrupts the FOXO4-p53 interaction holding senescent cells alive. Induced apoptosis selectively in senescent cells in experiments, but human systemic selectivity is unknown. Independent groups have published additional preclinical studies; they do not exactly replicate every original endpoint. Human treatment trials or published human administration were not found.

Proposed mechanism

The FOXO4-p53 axis in senescence. Senescent cells resist apoptosis by sequestering p53 in the nucleus via FOXO4 binding. FOXO4 localization and expression vary by tissue and context. The FOXO4-p53 complex keeps p53 locked away from mitochondria, preventing it from triggering intrinsic apoptosis. The peptide binds p53, and cell-culture selectivity does not establish safety in healthy human tissues.

D-retro-inverso (DRI) design. The peptide sequence is reversed and all L-amino acids swapped to D-amino acids. The design is intended to alter peptide stability and binding; human half-life, biodistribution and clinical advantage have not been established.

Selectivity rationale. FOXO4 expression and localization are context-dependent; a universal two-to-fivefold rule is not established. The peptide competitively disrupts FOXO4-p53 → p53 is released → p53 translocates to mitochondria → cytochrome c release → apoptosis. Selectivity in cultured cells cannot establish selectivity throughout a human body. This is the theoretical selectivity story. Whether it holds at therapeutic doses in humans is completely unknown.

Safety

  • Human adverse-event rates, pharmacokinetics, immunogenicity and contraindications not established.
  • A pulmonary-hypertension mouse study reported harmful pulmonary vascular effects.
  • Selectivity in cultured cells does not establish systemic human safety.

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence D senolytic anti-ageing

D stands. Cell, tissue and mouse data only (including one harmful mouse study); no human trial.

Human trials · 0

No human trials found for the marketed use.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

No data.

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

Not rated yet.

Sources

  1. fda.gov/media/94155/download
  2. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  3. pubmed.ncbi.nlm.nih.gov/28340339/
  4. pubmed.ncbi.nlm.nih.gov/31959736/
  5. pubmed.ncbi.nlm.nih.gov/39994346/
  6. pubmed.ncbi.nlm.nih.gov/41625068/
  7. pubmed.ncbi.nlm.nih.gov/40593617/
  8. pubmed.ncbi.nlm.nih.gov/39025385/
  9. pubmed.ncbi.nlm.nih.gov/36515093/
  10. pmc.ncbi.nlm.nih.gov/articles/PMC12216184/
  11. pmc.ncbi.nlm.nih.gov/articles/PMC11850796/
  12. pmc.ncbi.nlm.nih.gov/articles/PMC12852416/
  13. pmc.ncbi.nlm.nih.gov/articles/PMC5556182/
  14. pmc.ncbi.nlm.nih.gov/articles/PMC5556182
  15. pmc.ncbi.nlm.nih.gov/articles/5556182/
  16. pmc.ncbi.nlm.nih.gov/articles/PMC7053614/
  17. clinicaltrials.gov/search?term=FOXO4-DRI
  18. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c

Reddit threads read · 10

5 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.